Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
Antiviral compounds
US9511056B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9511056-B2 |
| Application number | US-201414280478-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 16, 2014 |
| Priority date | May 13, 2009 |
| Publication date | Dec 6, 2016 |
| Grant date | Dec 6, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of eliminating hepatitis C virus in a human patient in need thereof comprising administering to said human an effective amount of: (1) a compound of formula: and (2) a NS5B polymerase inhibitor. 2. The method of claim 1 , wherein the NS5B polymerase inhibitor is a nucleotide inhibitor of HCV NS5B polymerase. 3. The method of claim 2 , wherein the human is treated without interferon. 4. The method of claim 3 , wherein the human is treated without ribavirin. 5. The method of claim 3 , wherein the human is treated with ribavirin. 6. The method of claim 3 , wherein the human is infected with HCV genotype 1. 7. The method of claim 3 , wherein the human is infected with HCV genotype 1a or 1b. 8. The method of claim 4 , wherein the human is infected with HCV genotype 1. 9. The method of claim 4 , wherein the human is infected with HCV genotype 1a or 1b.
Assignees
Inventors
- Bacon Elizabeth M
- Canales Eda
- Cho Aesop
- Cottell Jeromy J
- Desai Manoj C
- Graupe Michael
- Guo Hongyan
- Halcomb Randall L
- Kato Darryl
- Kim Choung U
- Kirschberg Thorsten A
- Krygowski Evan S
- Lazerwith Scott E
- Link John O
- Liu Hongtao
- Liu Qi
- Mackman Richard L
- Mitchell Michael L
- Parrish Jay P
- Pyun Hyung-Jung
- Saugier Joseph H
- Schroeder Scott D
- Sun Jianyu
- Taylor James G
- Trenkle James D
- Tse Winston C
- Vivian Randall W
- Watkins William J
- Xu Lianhong
Classifications
containing three or more hetero rings · CPC title
containing three or more hetero rings · CPC title
- C07D401/14Primary
containing three or more hetero rings · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Boronic and borinic acid compounds · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9511056B2 cover?
- The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
- Who is the assignee on this patent?
- Gilead Pharmasset Llc
- What technology area does this patent fall under?
- Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).